Type

Range

Units

Status

Start Date

End Date

Financing

Brief description/objective

Multicenter, randomized, active comparator-controlled, double-blind,
double-dummy, parallel group, dose-finding Phase 2 study to compare
the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in
patients with atrial fibrillation

Primary Safety Endpoint
 composite of International Society on
Thrombosis and Hemostasis (ISTH) major
and clinically relevant non-major bleeding

Intervention over 12 weeks and Safety Follow up after 2 weeks